Immunotherapies, including immune checkpoints (PD-1/PD-L1, CTLA4, TIGIT, LAG3, and others) blockade (ICB) may overcome the pitfalls of these conventional anticancer drugs and produce prolonged responses through activation of cell-killing lymphocytes within the tumor microenvironment [2]. The gene discussed is CD274; the disease is neoplasm.